The drugmaker expects one-time restructuring costs of up to $2 billion as it redeploys resources over three years AstraZeneca $AZN +2.88% is launching a cost-savings program with $1.5 billion in annualized benefits to free up money for its drug pipeline, according to The…
NRx Pharmaceuticals (NRXP) stock gains as the FDA approves its generic ketamine injection, potentially easing supply constraints for therapy. Read more here. - NRx Pharmaceuticals (NRXP) added more than 15% in premarket trading on Friday after the FDA approved its generic ketamine…
Bambusa Therapeutics (BBTX) priced its upsized initial public offering at $16 per share, offering 10.56M common shares. The company expects to raise ~$168.9M in gross proceeds before offering expenses. Underwriters have been granted a 30-day option to purchase up to an additional 1.58M shares…
Nanobiotix stock hinges on J&J’s JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX. - Nanobiotix S.A. is now primarily dependent on J&J's development and commercialization of its lead asset,…
Repligen to issue $1B in 2031 convertible notes, refinance debt, and fund a share repurchase. - Repligen (RGEN) on Friday said it has entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% convertible senior notes due 2028 and…
Generic varenicline expected to launch next year, subsidiary secures exclusive Taiwan rights to melatonin tablet Oct. 30, 2026 19:10 TAIPEI (Taiwan News) — Anxo Pharmaceutical Co. has expanded its drug portfolio, securing approval for a smoking cessation drug and exclusive distribution rights for a…
The appetite for Nasdaq listings shows no signs of letting up, with Aspen Neuroscience and Bambusa Therapeutics getting their IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger. Boston, Massachusetts-based immunology and inflammation (I&I) specialist…
Tango Therapeutics earns a Buy upgrade after strong PDAC trial data. - Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. - Company's combination therapy showed an 82% ORR and 88% 9-month PFS,…
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition. Parkinson’s cell therapy developer Aspen Neuroscience on Thursday evening its initial public offering, raising…
Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility October 29, 2026 8:30 AM EDT Yaky Yanay - President, CEO & DirectorAlejandro Weinstein will follow the formal presentation. As a reminder, this webinar is being recorded. Yaky, please. Yaky YanayPresident, CEO & Director…
Biotechnology, gene editing, biopharma platforms, and clinical pipelines.
An article joins this feed when it matches these terms. Each one is also a search of its own.